News | Cardiovascular Clinical Studies | October 04, 2022

New Analysis of Soloist-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events

New analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, in the treatment of heart failure 

New analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, in the treatment of heart failure

Getty Images


October 4, 2022 — Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3outcomes trial of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, was presented at the Heart Failure Society of America (HSFA) Annual Scientific Meeting 2022. 

The new analysis was presented by Bertram Pitt, M.D., FACC, professor of medicine emeritus at the University of Michigan, School of Medicine, and co-chair for the SOLOIST-WHF trial as well as a member of the Executive Committee for the Phase 3 SCORED trial of sotagliflozin.  The poster, entitled “Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, Reduces First and Subsequent Heart Failure-related Events in Patients Admitted for Worsening Heart Failure”, was presented on Sunday, October 2nd during the general poster viewing session IV (https://hfsa.org/hfsa-annual-scientific-meeting-2022). 

“Patients treated with sotagliflozin in the SOLOIST-WHF trial experienced fewer single as well as multiple heart failure events than those receiving placebo,” said Dr. Pitt.  “Thus, we conclude that sotagliflozin altered the trajectory of patients hospitalized for worsening heart failure by reducing early and recurrent heart failure events.” 

“We are pleased that data from the SOLOIST-WHF trial continues to yield robust findings that further help characterize and differentiate the potential benefits of sotagliflozin in heart failure,” said Dr. Craig Granowitz, Lexicon’s senior vice president and chief medical officer. 

About the SCORED and SOLOIST-WHF Studies 

SCORED was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 10,584 patients with type 2 diabetes, chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73 m2 of body-surface area, and risks for cardiovascular disease. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.  Key secondary endpoints included total number of events of deaths from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke

SOLOIST-WHF was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.  

Both SCORED and SOLOIST-WHF achieved their respective primary endpoints, with overall tolerability similar to placebo across both trials.  Results from both studies were presented at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease” and “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” which may be accessed at www.nejm.org

 


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now